Pediatrix Medical Group (NYSE: MD) installs new general counsel after Moore exit

Q: How is Mary Ann E. Moore’s departure from Pediatrix (MD) classified?

The company classifies Mary Ann E. Moore’s transition as a termination without cause under her Second Amended and Restated Employment Agreement. She will receive the benefits specified in that employment agreement in connection with this transition.

Q: Who has been appointed new General Counsel at Pediatrix Medical Group (MD)?

Pediatrix Medical Group has appointed David Haddock as Executive Vice President, General Counsel and Secretary. His appointment is disclosed alongside the Separation Agreement and planned transition of former General Counsel Mary Ann E. Moore.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Pediatrix Medical Group, Inc. reports that Mary Ann E. Moore, previously Executive Vice President, General Counsel, Chief Administrative Officer and Secretary, has entered into a Separation Agreement with subsidiary PMG Services, Inc. Under this agreement, she will serve in an advisory role until October 31, 2026, when her employment with the company will end.

The company states that Ms. Moore’s transition is treated as a termination without cause under her Second Amended and Restated Employment Agreement, and she will receive the benefits specified in that agreement. Pediatrix also reports the appointment of David Haddock as Executive Vice President, General Counsel and Secretary.

8-K Event Classification

2 items: 5.02, 7.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Figures

Advisory role end date: October 31, 2026 Separation Agreement date: July 21, 2026 Initial transition decision date: May 1, 2026

3 metrics

Advisory role end date October 31, 2026 Date Ms. Moore’s advisory role and employment with Pediatrix end

Separation Agreement date July 21, 2026 Date Ms. Moore and PMG Services, Inc. entered into the Separation Agreement

Initial transition decision date May 1, 2026 Date the company and Ms. Moore determined she would transition from her role

Key Terms

Separation Agreement, termination without cause, Regulation FD Disclosure, Executive Vice President, General Counsel and Secretary

4 terms

Separation Agreement regulatory

"Ms. Moore and PMG Services, Inc. entered into a Separation Agreement pursuant to which"

A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.

termination without cause regulatory

"Ms. Moore’s transition from the Company is a termination without cause under that certain"

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. The Company has appointed Mr. David Haddock"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Executive Vice President, General Counsel and Secretary financial

"appointed Mr. David Haddock as Executive Vice President, General Counsel and Secretary"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/24/2026 - 05:00 PM Accepted by SEC EDGAR 07/24/2026 - 05:00 PM

FAQ

What executive leadership change did Pediatrix Medical Group (MD) announce?

Pediatrix Medical Group announced that Mary Ann E. Moore will leave her roles after serving in an advisory capacity through October 31, 2026. The company also appointed David Haddock as Executive Vice President, General Counsel and Secretary.

When will Mary Ann E. Moore fully transition out of Pediatrix Medical Group (MD)?

Mary Ann E. Moore will remain in an advisory role to Pediatrix Medical Group until October 31, 2026. On that date, she will transition from the company pursuant to the terms of her Separation Agreement with PMG Services, Inc.

How is Mary Ann E. Moore’s departure from Pediatrix (MD) classified?

The company classifies Mary Ann E. Moore’s transition as a termination without cause under her Second Amended and Restated Employment Agreement. She will receive the benefits specified in that employment agreement in connection with this transition.

Who has been appointed new General Counsel at Pediatrix Medical Group (MD)?

Pediatrix Medical Group has appointed David Haddock as Executive Vice President, General Counsel and Secretary. His appointment is disclosed alongside the Separation Agreement and planned transition of former General Counsel Mary Ann E. Moore.

What agreement governs Mary Ann E. Moore’s benefits upon leaving Pediatrix (MD)?

Mary Ann E. Moore’s benefits upon leaving are governed by her Second Amended and Restated Employment Agreement. The company states she will receive the benefits specified in that agreement due to her termination without cause.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): July 21, 2026

    

Pediatrix Medical Group, Inc.

(Exact name of Registrant as Specified in Its Charter)


Florida	001-12111	26-3667538
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1301 Concord Terrace
Sunrise, Florida		33323
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 954 384-0175

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.01 per share	MD	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported, on May 1, 2026, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”) and Ms. Mary Ann E. Moore determined that Ms. Moore would transition from her role as the Executive Vice President, General Counsel, Chief Administrative Officer and Secretary of the Company prior to the end of the calendar year. On July 21, 2026, Ms. Moore and PMG Services, Inc., a wholly-owned subsidiary of the Company (“PMG”), entered into a Separation Agreement pursuant to which Ms. Moore will serve in an advisory role to the Company until October 31, 2026 and transition from the Company effective as of such date. Ms. Moore’s transition from the Company is a termination without cause under that certain Second Amended and Restated Employment Agreement between Ms. Moore and PMG, and Ms. Moore will receive the benefits specified therein.

Item 7.01 Regulation FD Disclosure.

The Company has appointed Mr. David Haddock as Executive Vice President, General Counsel and Secretary of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Pediatrix Medical Group, Inc.

Date:	July 24, 2026	By:	/s/ Kasandra H. Rossi
			Kasandra H. Rossi Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document